Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 520 entries
View as:

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00215982 Org: User:
Start: 12/31/04 End: 07/31/07 Due: 07/31/08

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02586675 Org: User:
Start: 02/23/16 End: 10/27/21 Due: 10/27/22

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00231465 Org: User:
Start: 07/31/03 End: 08/31/12 Due: 08/31/13

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01005745 Org: User:
Start: 10/20/09 End: 01/31/26 Due: 01/31/27

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Phase: N/A Priority: Normal
NCT ID: NCT03495427 Org: User:
Start: 12/18/19 End: 05/31/29 Due: 05/31/30

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01659151 Org: User:
Start: 08/03/12 End: 09/30/25 Due: 09/30/26

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Phase: N/A Priority: Normal
NCT ID: NCT00747643 Org: User:
Start: 09/30/08 End: 08/31/10 Due: 08/31/11

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02218164 Org: User:
Start: 08/12/14 End: 06/25/18 Due: 06/25/19

Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma

Phase: N/A Priority: Normal
NCT ID: NCT02611037 Org: User:
Start: 03/04/16 End: 01/26/24 Due: 01/26/25

Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE

Phase: N/A Priority: Normal
NCT ID: NCT04150874 Org: User:
Start: 02/19/20 End: 05/14/21 Due: 05/14/22

Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)

Phase: N/A Priority: Normal
NCT ID: NCT06305676 Org: User:
Start: 01/22/24 End: 01/31/29 Due: 01/31/30

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Phase: N/A Priority: Normal
NCT ID: NCT06337552 Org: User:
Start: 04/04/24 End: 03/31/27 Due: 03/31/28

Depocyt® With Sorafenib in Neoplastic Meningitis

Phase: N/A Priority: Normal
NCT ID: NCT00964743 Org: User:
Start: 08/31/09 End: 02/28/11 Due: 02/28/12

Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2

Phase: N/A Priority: Normal
NCT ID: NCT00031564 Org: User:
Start: 05/31/00 End: 06/30/12 Due: 06/30/13

Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01446952 Org: User:
Start: 09/30/11 End: 04/30/16 Due: 04/30/17

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Phase: N/A Priority: Normal
NCT ID: NCT00720096 Org: User:
Start: 07/31/08 End: 10/31/09 Due: 10/31/10

Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00101166 Org: User:
Start: 10/31/04 End: 03/31/10 Due: 03/31/11

Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00776295 Org: User:
Start: 05/31/07 End: 08/31/10 Due: 08/31/11

CI-994 in Treating Patients With Advanced Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00005624 Org: User:
Start: 08/31/97 End: 02/28/03 Due: 02/28/04

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04975152 Org: User:
Start: 10/22/21 End: 03/31/28 Due: 03/31/29

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT01048723 Org: User:
Start: 01/31/10 End: 10/31/11 Due: 10/31/12

Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03137693 Org: User:
Start: 11/29/17 End: 01/27/20 Due: 01/27/21

Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03177291 Org: User:
Start: 09/26/17 End: 12/04/24 Due: 12/04/25

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

Phase: N/A Priority: Normal
NCT ID: NCT01776723 Org: User:
Start: 02/20/13 End: 05/10/22 Due: 05/10/23

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT01286038 Org: User:
Start: 04/06/11 End: 11/03/18 Due: 11/03/19